Clinical studies with the specific 'pure' antioestrogen ICI 182780

Breast

Volumn 5, Issue 3, 1996, Pages 192-195

  Howell, A ^a   DeFriend, D J ^b   Robertsont, J F R ^c   Blamey, R W ^c   Anderson, L ^a   Anderson, E ^e   Sutcliffe, F A ^d   Walton, P ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

ADVANCED CANCER; BONE DENSITY; BREAST CANCER; CONFERENCE PAPER; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; REMISSION; TUMOR GROWTH;

EID: 0030055052     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(96)90092-2     Document Type: Conference Paper

References (16)

1. Cole M P, Jones C T A, Todd I D H. A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI 146474. Br J Cancer 1971; 25: 270-275.
2. Nicholson R I, Francis A B, Kyme S, Gee JMW. Properties and mode of action of pure antioestrogen in breast cancer in vitro. The Breast 1996; 5: 00-00.
3. Osborne C K. Athymic nude mouse model for the study of new antioestrogens in breast cancer. The Breast 1996; 5: 00-00.
4. Howell A, Dodwell D, Anderson H, Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992; 3: 611-617.
5. Bucout R, Vignau M, Torelli V et al. New biospecific adsorbents for the purification of oestradiol receptor. J Biol Chem 1978; 253: 8221-8228.
6. Harper M J K, Walpole A L A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967; 13: 101-119.
7. Wakeling A E, Dukes M, Bowler J A. Potent specific pure antioestrogen with clincal potential. Cancer Res 1991; 51: 3867-3873.
8. Anderson E, Nicholson R, Dowsett M, Howell A. Models of new antioestrogen in vivo: primary tumours. The Breast 1996; 5: 00-00.
9. De Friend D, Anderson E, Bell J, Wilks D P, West C M L, Howell A. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70: 204-211.
10. Dukes M, Waterton J C, Wakeling A E. Antiuterotrophic effects of the pure antioestrogen ICI 182780 in adult female monkeys (Macaca-nemestrina): quantitive magnetic resonance imaging. J Endocrinol 1993; 138: 203-210.
11. Howell A, DeFriend D J, Robertson J F R et al. Pharmacokinetics, systemic and antitumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer, 1996. In press.
12. Dukes M, Chester R, Yarwood L, Wakeling A E. Effects of non-steroidal pure antioestrogen, ZM 189154 on oestrogen target organs of the rat including bones. J Endocrinol 1994; 141: 335-341.
13. Wade G N, Blaustein J D, Gray J M, Meredith J M. ICI 182780: a pure antioestrogen that affects behaviours and energy balance in rats without acting in the brain. Am J Physiol 1993; 265: R1392-R1398.
14. Thomas E J, Thomas N M, Walton P L, Dowsett M. The effects of ICI 182780, a pure antioestrogen, on reproductive endocrinology in normal, pre-menopausal women. J Endocrinol 1993; 137s: 183.
15. Wakeling A E. The future of new pure antioestrogens in clinical breast cancer. Breast Cancer Res Treat 1993; 25: 1-9.
16. Gallagher A, Chambers T J, Tobias J H. The estrogen antagonist ICI 182780 reduces cancellous bone volume in female rats. Endocrinology 1993; 133: 2787-2791.